| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 18632461 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 103 journal articles in the PubMed database | Email to a friend | | |
| Reddy GK, Mughal TI, Roodman GD
Novel approaches in the management of myeloma-related skeletal complications. [Journal Article]
Support Cancer Ther 2006 Oct 1; 4(1):15-8.
Abstract | Full Citation | Find Related Articles | | Oyajobi BO, Mundy GR
Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. [Evaluation Studies, Journal Article]
Cancer 2003 Feb 1; 97(3 Suppl):813-7.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Hofbauer LC, Neubauer A, Heufelder AE
Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. [Journal Article, Review]
Cancer 2001 Aug 1; 92(3):460-70.
Abstract | Full Citation | Find Related Articles | | Keller ET
The role of osteoclastic activity in prostate cancer skeletal metastases. [Journal Article, Review]
Drugs Today (Barc) 2002 Feb; 38(2):91-102.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Mera K, Ito K
[Therapeutic agents for disorders of bone and calcium metabolism. Denosumab : A Fully Human Monoclocal AntibodyTargeting RANKL as a Therapy for Cancer-induced Bone Diseases.] [English Abstract, Journal Article]
Clin Calcium 2007 Jan; 17(1):37-46.
Abstract | Full Citation | | Vega D, Maalouf NM, Sakhaee K
The Role of RANK/RANKL/OPG: Clinical Implications. [JOURNAL ARTICLE]
J Clin Endocrinol Metab 2007 Sep 25.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Hamdy NA
Denosumab: RANKL inhibition in the management of bone loss. [Journal Article]
Drugs Today (Barc) 2008 Jan; 44(1):7-21.
Abstract | Full Citation | Find Related Articles | | Body JJ, Facon T, Coleman RE, et al.
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. [Journal Article, Multicenter Study, Randomized Controlled Trial]
Clin Cancer Res 2006 Feb 15; 12(4):1221-8.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Lobato JV, Rodrigues JM, Cavaleiro MV, et al.
Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates. [Journal Article]
Acta Med Port 2007 Mar-Apr; 20(2):185-92.
Abstract | Full Citation | Find Related Articles |   |
|
| | Enter
www.unboundmedicine.com/medline
in your iPhone browser
or View our
Unbound MEDLINE
iPhone demo
Advertise on this site.
|
